Our research integrates the study of monocytes, macrophages, and dendritic cells with vascular and lymphatic vessel biology. Atherosclerosis is a disease that merges these areas of research.

The goal of my research is to bridge bench to bedside to gain understanding of mechanisms responsible for athero-thrombotic and other vascular diseases, including angiogenesis. Our focus for nearly 25 years has been the vascular biology of the type B scavenger receptor CD36.

Our lab is focused on the mechanisms of injury associated with harvest, preparation, and preservation of human saphenous vein grafts. We are also interested in calcium independent smooth muscle relaxation. The laboratory has generated 3 patents and there are three therapeutics in preclinical development.

The Gerhardt lab is a joint venture between the Vascular Biology Lab (VBL) in London and the Vascular Patterning Lab (VPL) in Leuven seeking to foster new insights by establishing an interdisciplinary team that can draw inspiration from the diverse scientific environment present at the LRI and the VIB.

The primary focus of the laboratory is to delineate the role of the renin-angiotensin system on vascular pathology. In collaboration with the laboratory of Dr. Lisa Cassis during the early days of arriving at the University of Kentucky, initial studies examined the role of blood pressure in atherosclerosis.

Over the last 30 years, we have been interested in how intimal hyperplasia and stenosis/restenosis develop and the factors that determine outcome, particularly in vascular grafts.

The Dardik laboratory studies the healing and function of blood vessels and synthetic blood vessel substitutes that are used in patients having vascular bypass surgery.

n 2009, CICS was launched at Brigham and Women's Hospital (BWH) in collaboration with Kowa Company Ltd, a Japanese corporation.

Since the late 1990ies research efforts in our laboratory have been focused on the understanding of the functions of the Collagen Triple Helix Repeat Containing-1 (Cthrc1), a molecule discovered in our laboratory in 1999 in the adventitia of injured arteries.

Endothelial cell Biology and hereditary hemorrhagic telangiectasia (HHT)

Our lab focuses on ligand receptor interactions that promote cellular and tissue injury.

The Pulmonary Hypertension Research Group is a collaboration of clinicians and researchers working together to reveal the pathogenesis of PH, identify the mechanisms of the disease, and develop new therapeutic approaches in order to improve the care of patients with PH.